Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.
Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference1.0%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedResults were posted on December 17, 2024, following the previous submission of results on November 21, 2024.SummaryDifference1.0%
- Check31 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
- Check39 days agoChange DetectedThe website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check46 days agoChange DetectedResults have been submitted, replacing the previous status of no results posted.SummaryDifference0.5%
- Check53 days agoChange DetectedOn November 21, 2024, new content was added, while on October 29, 2024, a detailed section regarding data download options and study information fields was removed.SummaryDifference14%
Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.